Biodesix price target lowered to $2 from $3 at Scotiabank

Scotiabank lowered the firm’s price target on Biodesix (BDSX) to $2 from $3 and keeps an Outperform rating on the shares. The company’s Q1 revenue miss and FY25 revenue guidance reduction can be attributed to the shift in the company’s commercial strategy, the analyst tells investors. The firm continues to believe the market for lung nodule risk assessment is a multi-billion-dollar opportunity that is under-penetrated and the company faces minimal competition.